Stock MEDCL MEDINCELL S.A.
Add to a list
To use this feature you must be a member
Log inSign up

News MedinCell S.A.

Equities

MEDCL

FR0004065605

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 11:35:11 2025-01-24 am EST 		5-day change 1st Jan Change
15.98 EUR +0.63% Intraday chart for MedinCell S.A. -1.96% -3.85%
Dec. 13 Eutelsat: delisted from the SBF 120 and CAC Mid 60 indices CF
Dec. 13 Euroapi: delisted from the SBF 120 and CAC Mid 60 indices CF

Search
See the results
Medincell: Publication of the 2025 Financial Calendar
Jan. 15
 BU
Eutelsat: delisted from the SBF 120 and CAC Mid 60 indices
Dec. 13
 CF
Euroapi: delisted from the SBF 120 and CAC Mid 60 indices
Dec. 13
 CF
Casino: delisted from the SBF 120 and CAC Mid 60 indices
Dec. 13
 CF
Casino exits SBF 120, Medincell, Planisware and Robertet included
Dec. 13
 RE
Medincell joins the SBF 120 and CAC Mid 60 indexes
Dec. 13
 CF
Medincell to Join the Euronext SBF 120 Index
Dec. 12
 BU
Medincell to Join the Euronext SBF 120 Index
Dec. 12
 BU
MedinCell S A : Half-Year Report
Dec. 10
 PU
MedinCell S A : Consolidated Half-Year Financial Results
Dec. 10
 PU
MedinCell S.A. Provides Earning Guidance for the Year Ending March 31, 2025
Dec. 10
 CI
MedinCell S.A., H1 2025 Earnings Call, Dec 10, 2024
Dec. 10
Medincell Publishes Its Consolidated Half-year Financial Results
Dec. 10
 BU
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2024
Dec. 09
 CI
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
Dec. 09
 BU
Medincell: positive results in arthroplasty
Dec. 09
 CF
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
Dec. 09
 BU
Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024
Nov. 28
 BU
Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3
Nov. 06
 BU
Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3
Nov. 06
 BU
Encouraging data revealed for schizophrenia long-acting injectables
Nov. 05
 AQ
Medincell: in the green with study data
Nov. 04
 CF
Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241
Nov. 04
 BU
Medincell’s partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241
Nov. 04
 BU
MedinCell S A : Participation in Leading Investor Conferences
24-10-29
 PU
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. News MedinCell S.A.